Alexion is focused on providing innovative treatments to patients with life-threatening rare diseases for which there are few, if any, effective treatment options. Alexion established operations in Sydney in 2008 to serve patients in the Australian region. We aim to work in partnership with stakeholders including healthcare providers, patient advocacy organisations, and government in order to best serve patients. By expanding the knowledge and awareness of rare diseases, we aim to help the medical community improve the process for diagnosis and treatment. Our goal is to bring hope to patients and families by delivering life-changing therapies.
In Australia, SOLIRIS® (eculizumab rmc) is registered for the treatment of atypical haemolytic uraemic syndrome (aHUS) and paroxysmal nocturnal haemoglobinuria (PNH) to reduce haemolysis, and for the treatment of adult patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive. These three are devastating, ultra-rare, complement-mediated diseases. SOLIRIS is listed on the Pharmaceutical Benefits Scheme (PBS) as a Section 100 item for aHUS and PNH. For the treatment of NMOSD, SOLIRIS is not reimbursed on the PBS. Product Information for SOLIRIS can be accessed here and Consumer Medicine Information here.
ULTOMIRIS® (ravulizumab rch) is registered in Australia for the treatment of PNH and aHUS, as an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis (gMG) who are anti-acetycholine receptor (AChR) antibody-positive. ULTOMIRIS® is listed on the PBS as a Section 100 item for the treatment of adults with PNH. Ultomiris is not listed on the PBS for the treatment of paediatric PNH, aHUS or treatment of adult patients with gMG who are AChR antibody-positive. Product information can be accessed here and Consumer Medicine Information here.
STRENSIQ® (asfotase alfa rch) is registered in Australia for the treatment of paediatric-onset hypophosphatasia (HPP). STRENSIQ is funded under the Life Saving Drugs Program for perinatal or infantile-onset HPP. Product Information for STRENSIQ can be accessed here and Consumer Medicine Information here.
KANUMA® (sebelipase alfa rce) is registered in Australia for the treatment of lysosomal acid lipase deficiency (LAL-D) in patients of all ages. LAL-D is a progressive and ultra-rare metabolic disease. KANUMA® is funded under the Life Saving Drugs Program for infantile-onset LAL-D. Product information for KANUMA can be accessed here and Consumer Medicine Information here.
Alexion is committed to seeking government reimbursement for KOSELUGO® (selumetinib), registered in Australia for the treatment of paediatric patients aged 2 years and above, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Product information for KOSELUGO can be accessed here and Consumer Medicine Information here.
▼ Soliris, Ultomiris and Koselugo are subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
How We Engage With Patients
We seek to understand and incorporate insights from people living with rare diseases and their caregivers into our development plans, medicines, and services. Our promise is to partner with the rare disease community to understand the patient experience as the community searches for diagnosis, treatment, disease education, and condition management. We work closely with patient advocacy groups to realise shared ambitions whilst respecting the privacy and independence of all parties.
Everyday, we serve people living with rare and devastating diseases. Groundbreaking innovation and life-saving therapies, all driven by a team with a shared sense of purpose and dedication — that’s Alexion.
Join us to help patients and their families fully live their best lives. Browse job openings in Australia here: